All
Oracea phase 3 clinical trials show 'highly significant' results
July 1st 2005Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.
Clindamycin-tretinoin combo effective for acne
July 1st 2005National Report - Pooled results from two phase 3 clinical trials demonstrate the efficacy and safety of an investigational acne treatment combining clindamycin and tretinoin in a hydrogel base (Velac, Connetics), James J. Leyden, M.D., reported at the 63rd Annual Meeting of the American Academy of Dermatology.
Psoriasis: Treatment combinations require blend of art, science
July 1st 2005Dallas - Most patients with moderate to severe psoriasis are best treated with a combination of topical, phototherapy and/or systemic agents that can be used in a variety of sequences, says Alan Menter, M.D., chairman, division of dermatology, Baylor University Medical Center.
Nonablative light-based therapy evolving
July 1st 2005Las Vegas - Nonablative light-based therapy continues to evolve, and with recent innovations, that field has advanced into the use of combination therapies for better outcomes and the ability to simultaneously address both cosmetic and medical skin problems, said Mark S. Nestor, M.D., Ph.D., at the Fall & Winter Dermatology Conference here.
Economics focus of topical acne treatment comparison
July 1st 2005National report — Among topical medications for treating mild-to-moderate acne, antibiotics are the most cost-effective therapy for inflammatory acne while retinoids are the most cost-effective for clearing non-inflammatory lesions, according to the results of a pharmacoeconomic evaluation reported by Stefan Weiss, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology.
Botox dosing, techniques refined to target individual
July 1st 2005San Diego — For cosmetic facial problems, Botox (botulinum toxin A, Allergan) is no longer a stand-alone, one-size-fits-all treatment. Increasingly, doctors are modifying doses based on individual patient needs and combining Botox with soft tissue fillers.
Lasers enhance cosmesis of new surgical scars
July 1st 2005National report — Early treatment with either a 585-nm or a 595-nm pulsed-dye laser (PDL) can safely and significantly improve the appearance of surgical scars in patients with skin phototypes I-IV, according to results of a controlled trial undertaken by researchers from the University of Miami's department of dermatology and cutaneous surgery.
Psoriasis Challenge: pulsed dye vs. excimer lasers
July 1st 2005New Orleans — According to Saleem Taibjee, M.D., both the xenon chloride excimer laser and the pulsed dye laser (PDL) can deliver long-term remission for localized plaque psoriasis. On average, the excimer is more effective; however, for a subset of patients, PDL treatment works better.
Diphenhydramine: alternative to lidocaine
July 1st 2005National report — An intraoral infraorbital block with diphenhydramine 5.9 mg/cc is a safe and effective method for providing local anesthesia in patients undergoing correction of nasolabial folds and lip augmentation using the hyaluronic acid-based fillers. This method has advantages compared to the use of lidocaine, says Jennifer C. Cather, M.D.
PPV case offers treatment challenges
July 1st 2005Newport Beach, Calif. — Most dermatologists are unlikely to see patients with phacomatosis pigmentovascularis (PPV). Those who do, however, should know how to recognize and treat the condition with an eye toward preventing concomitant systemic symptoms.
Pruritis possibilities narrowed
July 1st 2005Boston — Determining which mediators are released in different inflammatory conditions may help dermatologists find the most effective way to treat itch, according to John Ansel, M.D. Researchers are making progress to understanding the pathophysiology of pruritus and applying it to patients, but both areas continue to require additional study, he adds.
Staying current with medical dermatology research
July 1st 2005San Francisco — Keeping up with new developments in medical dermatology requires vigilance and time, especially because study results are published in so many different journals. To help dermatologists stay abreast of research, John H. Epstein, M.D., presented at the Pacific Dermatologic Association meeting in Newport Beach, Calif. He synopsized various papers that have been published in the last two years in journals other than the Archives of Dermatology, the Journal of the American Academy of Dermatology and the Journal of Investigative Dermatology.
Keeping herpes infections contained
July 1st 2005Houston — Dermatologists need to urge patients with herpes infections to take a nucleoside analog drug daily to prevent the transmission of genital herpes, according to Stephen Tyring, M.D., Ph.D., M.B.A., professor of dermatology, University of Texas Health Sciences Center, Houston.
CoQ10 shows promising anti-tumor activity
July 1st 2005Results from in vitro and preclinical in vivo studies suggest that topically applied coenzyme Q10 (CoQ10) has exciting potential as a safe and effective anti-tumor agent for treating and preventing recurrence of skin cancer as well as other types of malignancies, say researchers from the department of dermatology and cutaneous surgery, University of Miami Leonard M. Miller School of Medicine.
Oracea phase 3 clinical trials show 'highly significant' results
July 1st 2005Newtown, Pa. — CollaGenex Pharmaceuticals announces the "highly significant" positive outcomes of two phase 3, double-blinded, placebo-controlled clinical trials designed to evaluate the safety and efficacy of Oracea for the treatment of rosacea.
New cell harvesting system 'more efficient,' Isologen says
July 1st 2005Exton, Pa. — Isolagen, which specializes in the development and commercialization of autologous cellular therapies for tissue regeneration, has designed an automated cellular expansion system (ACE) to propagate and harvest cells more efficiently and cost-effectively than other cell harvesting systems currently available.
Clinical investigator, trial totals declining
July 1st 2005National report — An apparent decline in the total numbers of U.S. principal investigators (PIs) and clinical trials could impact drug availability and, ultimately, the pharmaceutical industry's ability to innovate, according to a recent study.